Lamotrigin beta ( DrugBank: - )
2 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 34 | 神経線維腫症 | 1 |
| 195 | ヌーナン症候群 | 1 |
34. 神経線維腫症
臨床試験数 : 137 / 薬物数 : 213 - (DrugBank : 76) / 標的遺伝子数 : 87 - 標的パスウェイ数 : 200
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2016-005022-10-DE (EUCTR) | 13/02/2018 | 09/11/2017 | Improvement of synaptic plasticity and cognitive function in RAS pathway disorders | Improvement of synaptic plasticity and cognitive function in RAS pathway disorders | Noonan Syndrom and Neurofibromatosis Type 1 MedDRA version: 20.0;Level: PT;Classification code 10029748;Term: Noonan syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 20.0;Classification code 10029268;Term: Neurofibromatosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Not possible to specify | Product Name: Lovastatin INN or Proposed INN: Lovastatin Other descriptive name: LOVASTATIN Product Name: Lamotrigin beta INN or Proposed INN: Lamotrigin | Technische Universität München, Fakultät für Medizin | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 30 | Phase 2 | Germany |
195. ヌーナン症候群
臨床試験数 : 14 / 薬物数 : 15 - (DrugBank : 5) / 標的遺伝子数 : 2 - 標的パスウェイ数 : 9
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2016-005022-10-DE (EUCTR) | 13/02/2018 | 09/11/2017 | Improvement of synaptic plasticity and cognitive function in RAS pathway disorders | Improvement of synaptic plasticity and cognitive function in RAS pathway disorders | Noonan Syndrom and Neurofibromatosis Type 1 MedDRA version: 20.0;Level: PT;Classification code 10029748;Term: Noonan syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 20.0;Classification code 10029268;Term: Neurofibromatosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Not possible to specify | Product Name: Lovastatin INN or Proposed INN: Lovastatin Other descriptive name: LOVASTATIN Product Name: Lamotrigin beta INN or Proposed INN: Lamotrigin | Technische Universität München, Fakultät für Medizin | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 30 | Phase 2 | Germany |